In recent years, biological products (biologics), including blood components, recombinant therapeutic proteins, antibodies, gene therapeutic materials, and so on, have been produced by biotechnology methods and other novel technologies. These products are essential therapeutic materials in progressive medicine. However, we often encounter the lower permeability of these biologics through biomembranes, due to their high molecular mass. In the last three decades, we have investigated drug delivery systems, including several enhancement methods for the permeability of biologics such as recombinant therapeutic proteins and viral vectors in epithelial cells. This review focuses the development of novel delivery systems for biologics in rectal and nasal administration, and includes an interesting observation of modulators of the tight junction (TJ) function. From cellular biology perspective, the interaction between permeability enhancing materials and targeted molecules in the TJ of epithelial cells was investigated. We elucidated that a TJ modulator will interact with a major constituent protein, for instance claudins, in playing an essential role in the tissue-speciˆc barrier function of the TJ. Furthermore, useful enhancement of gene transfer in cells (for instance, in Caco-2 cells) was found in the combination of an adenovirus vector and capric acid sodium salt (C10), a TJ modulator.
For the preparation of hollow-type suppositories, a freshly prepared solution of rhG-CSF was obtained by diluting the concentrated bulk solution of rhG-CSF to an appropriate concentration using a 10 mM acetate buŠer solution at pH 4.0. rhG-CSF dose ( mg/kg): 〇 , 100; □, 300; △, 600; ◇, 1000. Each point represents the mean±S.E. (vertical bar) of at least three rabbits. In the right panel, dotted line indicates values obtained after administration of suppository without rhG-CSF (control experiment). Statistically signiˆcant diŠerences: a) p＜0.05 in 600 or 1000 mg/kg vs. control value (without rhG-CSF); b) p＜0.05 in 300, 600 or 1000 mg/ kg vs. control value (without rhG-CSF). Nitric oxide (NO) donor: S-nitroso-N-acetyl-DL-penicillamine (SNAP); NO scavenger: 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide sodium salt (Carboxy-PTIO); peroxynitrite scavenger: glutathione. Cmax: the peak serum G-CSF concentration; tmax: the time required to reach the peak serum G-CSF concentration; AUC: area under the serum G-CSF concentration-time curve; MRT: the mean residence time; AUL: the area under the increased total blood leukocyte count-time curve. Each value represents the mean±S.E. from at least three experiments. Statistically signiˆcant diŠerences: a p＜0.05 for rhG-CSF (100 mg/kg) preparation containing SNAP and carboxy-PTIO vs. that (100 mg/ kg) containing no scavengers. C-CPE: the C terminus of Clostridium perˆringens enterotoxin (CPE) without the N terminus involved in its cytotoxicity. Rat jejunum or colon was treated with ‰uorescein isothiocyanate-labeled dextran (FD) 4000 (FD-4) in the presence of 40 mg/mL capric acid (sodium salt, C10) or 0.1 mg/mL C-CPE. FD-4 concentration in plasma, collected from the carotid artery, was determined at the indicated points. Data are expressed as the mean±S.E. (n ＝4). Binding to claudin was assayed by a competition assay using C-CPE-PSIF (C-CPE fused protein synthesis inhibitory factor). Modulation of the TJ barrier was determined by a transepithelial electric resistance (TER) assay using Caco-2 monolayer. Jejunal absorption was based on an in situ loop assay using rat jejunum. Yes and No indicate whether each function is important to the eŠectiveness of C-CPE, respectively. (A): A typical time course of TER in MDCK(Sec61b-) and MDCK (Sec61b＋). C-CPE was added at t＝0 and removed at t＝24 h to allow recovery; Key: □, MDCK(Sec61b-); ■, MDCK(Sec61b＋). Phases 1, 2, and 3 are deˆned as t＜0, 0  t＜24 h, and t24 h, respectively. (B): Deˆni-tion of T1/2 in phases 2 and 3. T1/2 is deˆned as TERN(t)＝1/2. Note that TER N (t) is extrapolated to zero to compensate for none-zero TER N (t) at t＝ 24 h in phase 3. In this particular case, T 1/2 in phases 2 and 3 were 2.5 and 14.0 h, respectively. (C): T 1/2 during phase 2 and 3 in MDCK(Sec61b-) (open column) and MDCK(Sec61b＋) (ˆlled column);  p＜0.05, denoting signiˆcant diŠerences in results from at least four independent experiments performed in triplicate. 
